New drug combo aims to stall advanced breast cancer
NCT ID NCT07037199
First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 23 times
Summary
This study tests a two-step treatment plan for 45 women with a certain type of advanced breast cancer (HR+/HER2-low). First, they receive a targeted drug called trastuzumab rezetecan for several months. Then, they switch to a combination of a CDK4/6 inhibitor and hormone therapy. The goal is to see how long the cancer stays under control and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen Memorial Hospital
RECRUITINGGuangzhou, Guangdong, 510120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.